Clinical outcomes of surgical and imatinib treatment for rectal gastrointestinal stromal tumours: retrospective cohort study.
Shunsuke TsukamotoYoshitaka HonmaHirokazu ShojiHidekazu HiranoManabu InoueYasuyuki TakamizawaKonosuke MoritaniJun ImaizumiYukihide KanemitsuPublished in: BJS open (2022)
Treatment with imatinib for rectal GISTs seems to improve outcomes, and neoadjuvant imatinib increases the rate of sphincter-preserving surgery.